India's Most Innovative Eyewear Company 2026: 6 Patents, 9 Papers

By Suraj Dubey | Senior Optometrist, Founder & Head of R&D, Sleepaxa Private Limited

Last updated: April 2026

Disclaimer: This article is for educational purposes only. Sleepaxa products are designed for visual comfort and light management, not as medical treatments. Consult a healthcare professional for persistent symptoms.

When we started Sleepaxa in 2023, India had zero domestic patents in photobiological eyewear. Every FL-41 migraine lens was imported. Every amber sleep lens was a generic tint without spectral precision. The concept of "photobiological eyewear" didn't exist in the Indian optical vocabulary.

Two years later, we hold 6 patents (1 granted, 3 pending), have published 9 research papers with permanent DOIs, and operate India's only photobiology-focused R&D lab. We didn't just enter an existing market. We built a new category.

This is the story of how an Indian optometrist-led startup is building the future of eyewear, one patent at a time.

Why Research-Driven Eyewear Matters in 2026

The global eyewear industry is worth over $180 billion. But most of it sells fashion. Very few companies invest in photobiology, the science of how light interacts with your biology.

Here's the problem: 213 million Indians suffer from migraine (GBD 2019). 25.7% have insomnia (medRxiv meta-analysis). 1.1 trillion hours are spent on smartphones annually. And the standard optical industry response? A generic blue light coating that a Cochrane review of 17 clinical trials found has limited evidence of benefit.

India needed a company that starts with science, not marketing. That's Sleepaxa.

6 Patents That Define India's Photobiological Eyewear Future

The Sleepaxa Innovation Timeline

How This Changes What You Wear on Your Face

Most eyewear companies sell frames. We engineer what goes inside them.

The traditional eyewear industry operates on a simple model: buy generic lenses from a supplier, put them in fashionable frames, market them with vague claims like "blocks blue light." Nobody asks: which blue light? How much? At what wavelength? For what condition?

Sleepaxa operates differently. Every lens starts with a photobiological question:

For migraine: Which retinal pathways amplify headache pain when stimulated by light? Answer: ipRGC-melanopsin (460-490 nm) + cone-driven (585-600 nm). Solution: NeuroCalm FLX+ dual-band attenuation. Shop FL-41 Migraine Glasses India

For sleep: What spectral range must be blocked to prevent evening melatonin suppression? Answer: 460-560 nm (complete melanopsin envelope). Solution: Circadian560 amber filtration. Shop Amber Sleep Glasses India

For daytime screen work: How do you reduce HEV glare without suppressing alerting blue? Answer: Filter 400-450 nm, preserve 460-490 nm. Solution: DayActive 1.0 yellow tint. Shop DayActive Gaming & Computer Glasses India

For light environment assessment: How do you measure if your room LED is circadian-safe? Answer: 14-channel spectral sensor + CIE S026 + CSAS scoring. Solution: VYLO portable device.

Why Research-Driven Matters: Sleepaxa vs Traditional Eyewear Brands

Photobiological Eyewear for Biohackers: The Science of Light Optimisation

If you're into biohacking, circadian optimisation, or performance science, you already know that light is the most powerful zeitgeber (time-giver) for your circadian clock. But most biohacking glasses are just generic amber lenses with no spectral data.

Sleepaxa's approach is different because it's built on published science:

Morning protocol: DayActive 1.0 (yellow tint) filters harsh HEV while preserving 460-490 nm alerting blue. Your brain gets the circadian entrainment signal it needs for peak morning cortisol and daytime focus. Shop DayActive Biohacking Glasses India

Evening protocol: Circadian560 amber blocks the complete melanopsin range (460-560 nm). Worn 2-3 hours before sleep, it creates "virtual darkness" for your ipRGC system while you continue working, reading, or watching screens. Your melatonin production begins on schedule. Shop Circadian Glasses India

Migraine protocol: FL-41 backed by NeuroCalm FLX+ for all-day wear during and between attacks. 30-50% light reduction without dark adaptation. The only technology addressing both identified migraine pain pathways. Shop Migraine Glasses India

Assessment protocol: VYLO measures your environment. Know your light. Optimise your exposure. That's real biohacking, not guesswork.

Frequently Asked Questions

References

1. Noseda R, et al. (2010) Neural mechanism for headache exacerbation by light. Nat Neurosci. 13:239-245.
2. Noseda R, et al. (2016) Migraine photophobia from cone-driven pathways. Brain. 139:1971-1986.
3. Brainard GC, et al. (2001) Action spectrum for melatonin regulation. J Neurosci. 21:6405-6412.
4. Lockley SW, et al. (2022) Spectral sensitivity of circadian phase resetting. PNAS. 119:e2205301119.
5. Singh S, et al. (2023) Blue-light filtering lenses. Cochrane Database Syst Rev. 8:CD013244.
6. Good PA, et al. (1991) Tinted spectacles in childhood migraine. Cephalalgia.
7. Reyes N, et al. (2024) FL-41 neural pathway activation. Am J Ophthalmol. 259:172-184.
8. Burkhart K, Phelps JR (2009) Amber lenses and sleep. Chronobiol Int. 26:1602-1612.
9. GBD 2019 Diseases and Injuries Collaborators. Lancet. 2020;396:1204-1222.
10. Indian Patent Office. Patent No. 587746 / Application IN 587746. Granted April 2026.

Suraj Dubey is the Founder & Head of R&D at Sleepaxa Private Limited. Senior Optometrist, 10+ years clinical experience. 6 patents. 9 research papers. ORCID: 0009-0003-7510-9254